150 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 1
Kim et al.
2003, 12, 87-100. (c) Sorbera, L. A.; Revel, L.; Castaner, J. P32/
98: Antidiabetic Dipeptidyl-Peptidase IV Inhibitor. Drugs Fu-
ture 2001, 26, 859-864. (d) Weber, A. E. Dipeptidyl Peptidase
IV Inhibitors for the Treatment of Diabetes. J. Med. Chem. 2004,
47, in press.
10 mL/kg). Blood glucose levels were determined from tail
bleeds taken 20, 40, 60, and 120 min after dextrose challenge.
The blood glucose excursion profile from t ) 0 to t ) 120 min
was used to integrate an area under the curve (AUC) for each
treatment. Percent inhibition values for each treatment were
generated from the AUC data normalized to the dextrose-
challenged lean controls.
(8) (a) Zhao, K.; Lim, D. S.; Funaki, T.; Welch, J. T. Inhibition of
Dipeptidyl Peptidase IV (DPP-IV) by 2-(2-Amino-1-fluoro-pro-
pylidene)-cyclopetanecarbonitrile,
a Fluoroolefin Containing
Peptidomimetic. Bioorg. Med. Chem. 2003, 11, 207-215. (b)
Peters, J.-U.; Weber, S.; Kritter, S.; Weiss, P.; Wallier, A.;
Boehringer, M.; Hennig, M.; Kuhn, B.; Loeffler, B.-M. Amino-
methylpyrimidines as novel DPP-IV inhibitors: A 105-Fold
Activity Increase by Optimization of Aromatic Substituents.
Bioorg. Med. Chem. Lett. 2004, 14, 1491-1493. (c) Peters, J.-
U.; Hunziker, D.; Fischer, H.; Kansy, M.; Weber, S.; Kritter, S.;
Mu¨ller, A.; Wallier, A.; Ricklin, F.; Boehringer, M.; Poli, S. M.;
Csato, M.; Loeffler, B.-M. An Aminomethylpyrimidine DPP-IV
Inhibitor with Improved Properties. Bioorg. Med. Chem. Lett.
2004, 14, 3757-3578. (d) Peters, J.-U.; Weber, S.; Kritter, S.;
Weiss, P.; A.; Wallier, A.; Zimmerli, D.; Boehringer, Steger, M.;
Loeffler, B.-M. Aminomethylpyridines as DPP-IV inhibitors.
Bioorg. Med. Chem. Lett. 2004, 14, 3579-3580. (e) Coppola, G.
M.; Zhang, Y. L.; Schuster, H. F.; Russell, M. E.; Hughes, T. E.
1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidyl
Peptidase IV Inhibitors. Bioorg. Med. Chem. Lett. 2000, 10,
1555-1558. (f) Branner, K. A.; Carr, R. D.; Christiansen, L. B.;
Elm, T.; Ribel, U. A Structurally Novel Dipeptidyl Peptidase IV
Inhibitor: 7-Benzyl-1,3-dimethyl-8-piperazinoxanthine. Pre-
sented at the 28th National Medicinal Chemistry Symposium
of the American Chemical Society, San Diego, CA, June 8-12,
2002; Abstract 72.
Acknowledgment. We thank Mr. Joseph F. Leone,
Mr. Robert A. Frankshun, Drs. Joseph M. Laquidara,
Gerard R. Kiecykowski, and Philip Eskola of Synthetic
Services Group for large scale synthetic support. We also
thank Dr. Bernard Choi for providing high-resolution
mass spectral analyses. Use of the beamline 32-ID with
beamline management and support provided by staff
from IMCA-CAT at the Advanced Photon Source was
supported by the companies of the Industrial Macro-
molecular Crystallography Association through a con-
tract with Illinois Institute of Technology. Use of the
Advanced Photon Source was supported by the U. S.
Department of Energy, Office of Science, Office of Basic
Energy Sciences, under Contract No. W-31-109-Eng-38.
Supporting Information Available: The X-ray crystal-
lographic data of compound 1 bound to DPP-IV and purity data
for compounds 1 and 22-28. This material is available free of
charge via the Internet at http://pubs.acs.org..
(9) (a) Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.;
Jenkins, P. D.; Jones, D. M.; Szelke, M. 4-Cyanothiazolidides
as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV.
Bioorg. Med. Chem. Lett. 1996, 6, 2745-2748. (b) Villhauer, E.
B.; Brinkman, J. A.; Naderi, G. B.; Burkey, Dunning, B. E.;
Mangold, B. L.; Mone, M. D.; Russell, M. E.; Weldon, S. C.;
Hughes, T. E. 1-[2-[(5-Cyanopyridin-2-yl)amino]-ethylamino]-
acetyl-2-acetyl]-2-(S)-pyrrolidine: A Potent Selective, and Orally
Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyper-
glycemic Properties. J. Med. Chem. 2002, 45, 2362-2365. (c)
Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.;
Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.;
Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cy-
ano-(S)-pyrrolidine: A Potent Selective, and Orally Bioavailable
Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Prop-
erties. J. Med. Chem. 2003, 46, 2774-2789. (d) Magnin, D. R.;
Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Huang, Y.; Simpkins, L.
M.; Taunk, P. C.; Betebenner, D. A.; Robertson, J. G.; Abboa-
Offei, B. E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D. F.;
Malley, M. F.; Gougoutas, J. Z.; Khanna, A.; Huang, Q.; Han,
S.; Parker, R. A.; Hamann, L. G. Synthesis of Novel Potent
Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical
Stability: Interplay between the N-Terminal Amino Acid Alkyl
Side Chain and the Cyclopropyl Group of R-Aminoacyl-L-cis-4,5-
methanoprolinenitrile-Based Inhibitors. J. Med. Chem. 2004, 47,
2587. (e) Parmee, E. R.; He, J.; Mastracchio, A.; Edmondson, S.
D.; Colwell, L. E.; Eiermann, G.; Feeney, W. P.; Habulihaz, B.;
He, H.; Kilburn, R.; Leiting, B.; Lyons, K.; Marsilio, F.; Patel,
R.; Petrov, A.; di Salvo, J.; Wu, J. K.; Thornberry, N. A.; Weber,
A. E. 4-Aminocyclohexylglycine Analogs as Potent Dipeptidyl
Peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 43-
46. (f) Caldwell, C. G.; Chen, P.; He, J.; Parmee, E. R.; Leiting,
B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Eiermann, G. J.; Petrov,
A.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E.
Fluoropyrrolidine Amides as Dipeptidyl Peptidase IV Inhibitors.
Bioorg. Med. Chem. Lett. 2004, 14, 1265-1268. (g) Ashton, W.
T.; Dong, H.; Sisco, R. M.; Doss, G. A.; Leiting, B.; Patel, R. A.;
Wu, J. K.; Marsilio, F.; Thornberry, N. A.; Weber, A. E.
Diasteroselective Synthesis and Configuration-Dependent Activ-
ity of (3-Substituted-cycloalkyl)glycine Pyrrolidides and Thia-
zolidides as Dipeptidyl Peptidase IV Inhibitors. Bioorg. Med.
Chem. Lett. 2004, 14, 859-863.
References
(1) (a) Orsakov C. Glucagon-Like Peptide 1, a New Hormone of the
Enteroinsular Axis. Diabetologia 1992, 35, 701-711. (b) Zander,
M.; Madsbad, S.; Madsen, J. L.; Holst, J. J. Effect of 6-Week
Course of Glucagon-Like Peptide 1 on Glycaemic Control, Insulin
Sensitivity, and â-Cell Function in Type 2 Diabetes; a Parallel-
Group Study. The Lancet 2002, 359, 824-830.
(2) For recent reviews see: (a) Holst, J. J. Glucagon-Like Peptide 1
(GLP-1) a Newly Discovered GI Hormone. Gastroenterology
1994, 107, 1048-1055. (b) Drucker, D. J. Glucagon-Like Pep-
tides. Diabetes 1998, 47, 159-169. (c) Deacon, C. F.; Holst, J.
J.; Carr, R. D. Glucagon-Like Peptide 1: A Basis for New
Approaches to the Management of Diabetes. Drugs of Today
1999. 35, 159-170. (d) Livingston, J. N.; Schoen, W. R. Glucagon
and Glucagon-like Peptide-1. Annu. Rep. Med. Chem. 1999, 34,
189-198.
(3) (a) Wettergren, A.; Schjoldager, B.; Martensen, P. E.; Myhre,
J.; Christiansen, J.; Holst, J. J. Truncated GLP-1 (Proglucagon
72-107 Amide) Inhibits Gastric and Pancreatic Functions in
Man. Dig. Dis. Sci. 1993, 38, 665-673. (b) Nauck, M. A.;
Niedereichholz, U., Ettler, R.; Holst, J. J.; Orskov, C.; Ritzel,
R.; Schmigel, W. H. Glucagon-Like Peptide-1 Inhibition of
Gastric-Emptying Outweighs Its Insulinotropic Effects in Healthy
Humans. Am. J. Physiol. 1997, 273, E981-E988.
(4) Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J. J.; Astrup, A. The
Effect of Physiological Levels of Glucagons-Like Peptide-1 on
Appetite, Gastric Emptying, Energy and Substrate Metabolism
in Obesity. Int. J. Obes. 2001, 25, 781-792.
(5) (a) Reimer, M. K..; Holst, J. J.; Ahren, B. Long-Term Inhibition
of Dipeptidyl Peptidase IV Improves Glucose Tolerance and
Preservesislet Function in Mice. Eur. J. Endocrin. 2002, 146,
717-727. (b) Pospisilik, J. A.; Martin, J.; Doty, T.; Ehses, J. A.;
Pamir, N.; Lynn, F. C.; Piteau, S.; Demuth, H.-U.; McIntosh, C.
H. S.; Pederson, R. A. Dipeptidyl Peptidase IV Inhibitor Treat-
ment Stimulates â-Cell Survival and Islet Neogenesis in Strep-
tozotocin-Induced Diabetic Rats. Diabetes 2003, 52, 741-750.
(6) (a) Kieffer, T. J.; McIntosh, C. H. S.; Pederson, T. A. Degradation
of Glucose-Dependent Insulinotropic Polypeptide and Truncated
Glucagon-Like Peptide 1 In Vitro and In Vivo by Dipeptidyl
Peptidase IV. Endocrinology 1995, 136, 3585-3596. (b) Deacon,
C. F.; Nauck, M. A.; Toft-Nielson, M.; Pridal, L.; Willms, B.;
Holst, J. J. Both Subcutaneously and Intravenously Adminis-
tered Glucagons-Like Peptide 1 Are Rapidly Degraded from the
NH2-Terminus in Type II Diabetic Patients and in Healthy
Subjects. Diabetes 1995, 44, 1126-1131.
(10) (a) Xu, J.; Ok, H. O.; Gonzalez, E. J.; Colwell, L. F., Jr.;
Habulihaz, B.; He, H.; Leiting, B.; Lyona, K. A.; Marsilio, F.;
Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee,
E. R. Discovery of Potent and Selective â-Homophenylalanine
Based Dipeptidyl Peptidase IV Inhibitors. Bioorg. Med. Chem.
Lett. 2004, 14, 4759-4762. (b) Brockunier, L.; He, J.; Colwell,
L. F., Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.;
Marsilio, F.; Patel, R.; Teffera, Y.; Wu, J. K.; Thornberry, N. A.;
Weber, A. E.; Parmee, E. R. Substituted Piperazines as Novel
Dipeptidyl Peptidase IV Inhibitors. Bioorg. Med. Chem. Lett.
2004, 14, 4763-4766.
(7) For recent reviews see: (a) Villhauer, E. B.; Coppola, G. M.;
Hughes, T. E. DPP-IV Inhibition and Therapeutic Potential.
Annu. Rep. Med. Chem. 2001, 36, 191-200. (b) Drucker, D. J.
Therapeutic Potential of Dipeptidyl Peptidase IV Inhibitors for
the Treatment of Type 2 Diabetes. Exp. Opin. Investig. Drugs
(11) Weber, A, E., Kim, D.; Beconi, M.; Eiermann, G.; Fisher, M.;
He, H.; Hickey, G.; Jaspal, S.; Leiting, B.; Lyons, K.; Marsilio,
F.; McCann, P.; Moller, D. E.; Patel, R.; Petrov, A.; Pryor, K.;
Sinha Roy, R.; Wu, J. K.; Wyvratt, M.; Zhang, B. B.; Thornberry,